Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.

In addition, patients with LM exhibited a trend toward prolonged PFS compared to those without LM, although the difference did not reach statistical significance as determined by the log-rank test (PFS: 14.7 vs. 9.6 months, P = 0.932).

also in 111,027 other papers